

REMARKS

RESPONSE TO ELECTION/REQUIREMENT FOR RESTRICTION

The Applicants have been required to restrict their invention to one of the following groups: Group I drawn to a chemical compound and a pharmaceutical composition using a chemical compound of Formula I, Group II drawn to a method for modulating the *in vivo* activity of a kinase using a chemical compound of Formula I, and Group III drawn to a method of treating diseases or disorders with uncontrolled, abnormal, and/or unwanted cellular activities using a chemical compound of Formula I. The Applicants further are required to elect a single species for examination on the merits.

Applicants elect Group I and the species named 2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3*H*-pyrazolo[3,4-*c*]isoquinolin-5-yl)phenol and identified as compound 171 in Table 1 on page 43 of the Specification. The Applicants understand the election of this species to be provisional and that examination will be extended to the other Markush group members set forth in Group I should the elected species be found patentable.

It is believed that no fee is required with the submission of this response. Should additional fees be required to process this submission and any papers attached, the Commissioner is hereby authorized to charge the necessary fees to Deposit Account Number 50-1108.

Respectfully submitted,

July 14, 2009
Date

/Janice V. Rice/
Janice V. Rice, Reg. No. 50,606
Attorney for the Applicants

Exelixis, Inc.
Physical Address:
249 East Grand Avenue
South San Francisco, CA 94080-4804

Mailing Address:
PO Box 511
South San Francisco, CA 94083-0511
Tel. (650) 837-7553 (direct), Fax: (650) 837-8234